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Summary
Objectives—To identify venous thromboembolism (VTE) disease-susceptibility genes.
Patients/Methods—We performed in silico genome wide association (GWAS) analyses using
genotype data imputed to ~2.5 million single nucleotide polymorphisms (SNPs) from adults with
objectively-diagnosed VTE (n=1503), and controls frequency-matched on age and sex (n=1459;
discovery population). SNPs exceeding genome-wide significance were replicated in a separate
population (VTE cases, n=1407; controls, n=1418). Genes associated with VTE were resequenced.
Results—Seven SNPs exceeded genome-wide significance (P < 5 × 10-8); four on chromosome
1q24.2 (F5 rs6025 [Factor V Leiden], BLZF1 rs7538157, NME7 rs16861990 and SLC19A2
rs2038024) and three on chromosome 9q34.2 (ABO rs2519093 [ABO intron 1], rs495828,
rs8176719 [ABO blood type O allele]). The replication study confirmed a significant association
of F5, NME7, and ABO with VTE. However, F5 was the main signal on 1q24.2 as only ABO
SNPs remained significantly associated with VTE after adjusting for F5 rs6025. This 1q24.2
region was shown to be inherited as a haplotype block. ABO resequencing identified 15 novel
single nucleotide variations (SNV) in ABO intron 6 and the ABO 3’ UTR that were strongly
associated with VTE (P < 10-4) and belonged to three distinct linkage disequilibrium (LD) blocks;
none were in LD with ABO rs8176719 or rs2519093. Our sample size provided 80% power to
detect odds ratios=2.0 and 1.51 for minor allele frequencies=0.05 and 0.5, respectively (α=1 ×
10-8; 1% VTE prevalence).
Conclusions—Aside from F5 rs6025, ABO rs8176719 and rs2519093, and F2 rs1799963,
additional common and high VTE-risk SNPs among whites are unlikely.
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Venous thromboembolism, consisting of deep vein thrombosis (DVT) and its complication,
pulmonary embolism (PE), is a common and potentially fatal disease. The overall annual
VTE incidence among USA whites is 108 per 100,000 person-years; incidence rates increase
exponentially with age for both men and women, and for both DVT and PE.[1] For almost
one-quarter of PE patients, the initial clinical presentation is sudden death.[2] Family and
twin studies suggest that VTE is highly heritable (h2=0.62) and likely results from
multigenic action as well as environmental exposures.[3-5] Several genetic disorders or
mutations that affect the regulation of hemostasis have been associated with VTE in small
case-control studies or observed in high VTE-risk pedigrees.[6] These include mutations
that impair the anticoagulant pathway, up-regulate (e.g., prothrombin G20210A) or impair
downregulation of the procoagulant pathway (e.g., Factor V Leiden), downregulate
fibrinolysis, and up-regulate innate immunity. In a SNP-based candidate gene, case-control
study, we tested genetic variation within all known important components of the
anticoagulant, procoagulant, fibrinolytic and innate immunity pathways for an independent
association with VTE and found one or more SNPs within ABO, F2, F5, F11, KLKB1,
SELP and SCUBE1 were significantly associated with VTE, including Factor V Leiden (F5
rs6025 T [minor] allele), prothrombin G20210A, ABO non-O blood type (ABO rs8176719,
odds ratio [OR]=1.47, P=5.68×10-12), and a novel association with ABO rs2519093
(OR=1.68, P=8.08×10-16) that was independent of blood type.[7] A GWAS confirmed
associations of VTE with Factor V Leiden and with ABO loci (blood groups non-O and A2),
[8] and a second GWAS with a larger sample size and more dense genome-wide scan
genotype data found associations of VTE with the F11 and FGG loci.[9] We hypothesized
that genes within other pathways also are VTE disease-susceptibility genes. To test this
hypothesis, we performed a genome-wide association study on the same VTE case-control
(discovery) population used for our candidate gene study, and replicated all SNPs exceeding
genome-wide significance in a separate VTE case-control (replication) population. Finally,
we performed gene resequencing in order to identify potentially “causative” genetic
variation in LD with haplotype-tagged SNPs that were associated with VTE.
Materials and Methods
Discovery population
The discovery study population consisted 1503 VTE cases and 1459 controls
(Supplementary Table 1) from a candidate gene (CG) study, as previously described.[7] A
subset of the CG study, 1270 VTE cases and 1302 controls, who consented to sending their
leukocyte genomic DNA outside of the Mayo Clinic, and newly recruited cases and controls,
have genome-wide scan (GWS) genotype data. The Mayo Clinic IRB approved the study
protocol as well as the data sharing protocol administered through Database for Genotypes
and Phenotypes (dbGAP).
Genotyping
Candidate Gene (CG) study—Leukocyte genomic DNA was extracted, quantified and
diluted to the appropriate concentration for Illumina Infinium iSelect genotyping within the
Genotyping Core Laboratory of the Mayo Clinic Advanced GenomicsTechnology Center, as
previously described.[7] Genotyping controls included 2% sample replicates and a CEPH
trio for quality control. In addition, case and control DNA sample addresses were randomly
assigned across both the 96-well plate as well as the 12-address iSelect BeadChip, ensuring
approximately equal numbers of case and control DNA samples by each stratum to avoid
potential plate and chip effects, respectively. Genotyping results from high-quality control
DNA (SNP call rate ≥95%) were used to generate a cluster algorithm. Of the 14,612 SNPs
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submitted to Illumina from 764 genes within the anticoagulant, procoagulant, fibrinolytic
and innate immunity pathways, 1,585 SNPs (covering 1,100 LD bins) failed manufacture,
leaving 13,027 successfully genotyped SNPs. Four additional SNPs were custom genotyped
on TaqMan, leaving 13,031 SNPs for analysis.
Genome-wide Scan (GWS) study—The Center for Inherited Disease Research
(CIDR), one of two genotyping centers supported by the Gene, Environment Association
Studies Consortium (GENEVA) consortium,[10] genotyped DNA samples using the
Illumina Human660-Quad v.1_A BeadChip (Illumina) and DNA from a subset of CG cases
and controls that consented to sending their DNA outside Mayo. Similar to the CG study,
case and control DNA sample addresses were randomly assigned across 96-well plates
provided by CIDR while ensuring roughly equal percentages of cases and controls within
each plate. Genotype clusters for each SNP were determined using the Illumina BeadStudio
Module (version 3.3.7), and combined intensity data from 96.6% of samples were used to
define clusters and call genotypes. Overall, 99.9% of samples attempted (2,597 of 2,600
total) passed quality-control standards. Genotypes were not called if the quality score from
BeadStudio was <0.15. Both the mean SNP call rates and the mean sample call rates were
99.9%. Genotypes were released for 560,816 SNPs (99.88% of those attempted). Genotypes
were not released for autosomal SNPs with call rates <85%, >1 HapMap replicate error,
>9% difference in call rate between genders, <0.2 cluster separation or >11% difference in
heterozygote frequency. Duplicate samples from both HapMap and the study were included
on each plate. Four HapMap trios (parents and child) were included to detect Mendelian
inheritance errors (i.e., whether the alleles are incorrectly passed from each parent to the
child). Reproducibility rates in the raw data were 99.99% among 32 duplicated study
subjects. The genotype concordance in the 134 HapMap control samples was 99.8%.
Quality-control steps
For both CG and GWS studies, four main categories of quality-control flags were set for
autosomal SNPs: (i) unacceptably high rates of missing genotype calls (>5%), (ii) low minor
allele frequency (MAF) (<0.005), (iii) unacceptably high rates of Mendelian errors (>1) and
(iv) deviation from Hardy-Weinberg equilibrium (HWE, P<E-05). For the CG study, of the
SNPs perfoming well (12,477/13,031) 181 SNPs were excluded due a MAF<0.005 (n=127)
or a call rate <0.95 (n=54), leaving 12,296 SNPs (covering 10,456 bins) for the association
analysis. For the GWS study, we flagged 1,965 SNPs with >5% missing genotypes. A total
of 1,683 (1,115/1,135) SNPs were flagged overall (cases/controls) for HWE deviation at
P<E-05.
Population stratification
To test for “cryptic relatedness” in our population, we conducted a population structure
analysis on all participating subjects to document genetic diversity among our population.
Using 494 Ancestry Informative Markers (AIMS) available on both our candidate gene and
GWA studies,[11] we ran STRUCTURE on 2962 participants.[12] The triangle plot
provided a graphical representation of genetic structure of our participants plus 209
unrelated individuals from HapMap phase II populations (Yorubans [YRI]; European-
Americans from the CEPH collection [CEU]; Chinese from Beijing [CHB]; and Japanese
from Tokyo [JPT]), giving a clear sense of how our participants fall among the HapMap
reference populations (Supplementary Figure 1).
Replication population
SNPs exceeding genome-wide significance in the discovery population and not in LD within
a gene were genotyped in a separate replication population of 2,825 individuals (VTE cases,
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n=1407; controls, n=1418; Supplementary Table 3). Replication study leukocyte genomic
DNA samples were largely from Olmsted County, MN, USA residents with objectively-
diagnosed incident VTE over the 45-year period, 1966-2010, and previously-matched
Olmsted County resident controls, as previously described.[13-15] The replication case and
control sample size was augmented by leukocyte DNA from non-Olmsted County Mayo
Clinic patients identified as described for the CG study population.[7]
DNA resequencing
We selected a subset of the discovery VTE cases and controls for resequencing to take
advantage of the joint configuration of two ABO SNPs independently associated with VTE,
rs8176719 (ABO exon 6 deletion determining type O blood group) and rs2519093 (ABO
intron 1 tag SNP).[7] We randomly sampled 82 cases and 14 controls within 3 of the 9
potential allele frequency cells (Supplementary Figure 8). The rs8176719 alleles are --/--
(deletion is the major allele), --/G, and G/G (G is the minor allele). The rs2519093 alleles
are G/G (G is the major allele), A/G, and A/A (A is the minor allele). For each SNP, the
genotypes are represented as 0, 1, or 2 copies of the minor allele. We represented the joint
allelic configuration of the two SNPs with the number of copies of the rs8176719 minor
allele given first as 0/0 (both with 0 copies of the minor allele), 0/1, 0/2 (0 copies of the
rs8176719 minor allele), 1/0 (1 copy of the minor rs8176719 allele), 1/1, and 1/2, and 2/0 (2
copies of the rs8176719 SNP minor allele and 0 copies of the rs2519093 minor allele), 2/1,
and 2/2. From Supplementary Figure 8, one observes discrepancies between cases and
controls at the 0/0, 1/1 and 2/2 combinations. We randomly sampled from these three
combinations, taking one third of the case series. For each SNP, we had 28 cases with 0/0
copies of the minor allele, 27 cases with 1/1 copies of the minor allele; and 27 cases with the
combination of 2/2 copies of the minor allele. We compared these 82 cases with 14 controls
that do not have any of these combinations.
Capture of the target genomic regions was performed using the Agilent custom eArray. The
capturing probes (baits) of 120 bases in length were designed based on the paired-end
sequencing protocol with a tiling frequency of 3x. The standard repeat masked regions were
avoided based on the definition in the UCSC genome database. The repeat regions are
mostly in intronic regions of the genes.
Sequencing was performed using Illumina’s HiSeq 2000 sequencer. Twelve samples were
multiplexed in each lane of the 8-lane flow cell, and a total of 96 samples (82 VTE cases and
14 controls) were sequenced. The read qualities were examined by FastQC (http://
www.bioinformatics.bbsrc.ac.uk/projects/fastqc) which generates QC matrix from the
FASTQ files including per-base sequence qualities, per-sequence quality scores, per-base
nucleotide content, and sequence duplication levels. The FastQC tool also provides warnings
for parameters failing to pass QC thresholds. The paired-end 100-base reads were aligned to
human genome build 36 using Burrows Wheeler Aligner (BWA)[16] allowing 4% of editing
distance within a seed length of 32. If the sequence duplication levels failed to pass the
FastQC threshold, the duplicated reads were removed using the SAMtools’s rmdup method.
[17] The BWA alignment was then cleaned up and improved using the Genome Analysis
ToolKit (GATK)[18] by recalibration and local re-alignments. SNVs were called using
SNVMix[19] with a cut-off probability score of 0.8 based on our preliminary testing using a
HapMap CEPH subject sequenced by the 1000 genome project (data not shown), and
INDELs were called by GATK with default parameters setting.
The read depths of each of the A, C, G, T bases at each variant position, as well as the
average mapping quality score were provided by curating the BAM pile-up files using
SAMtools.[17] If an identified SNV was a known variant from dbSNP or 1000 Genomes
Project, the allele frequencies of CEU, YRI, and CHB/JPT populations from HapMap and
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1000 Genome Project were provided. Both SNVs and INDELs were annotated by batch
submission to the SeattleSeq server, and for SNVs additional annotations were acquired
using a locally or cloud installed SIFT.[20] The SNVs or INDELs within a user defined
distance (default: 5 bases) to exon-intron boundaries were flagged as potential splice
variants and the corresponding transcript IDs are provided.
Information was reported on genes hosting SNVs and INDELs, including (i) the KEGG
pathway(s) (http://www.genome.jp/kegg) to which the gene belongs; and (ii) tissue
expression specificity of the gene.
Statistical methods
GWS (Illumina 660Q; 557,112 SNPs) and CG (n=764 genes relevant to the anticoagulant,
procoagulant, fibrinolytic and innate immunity pathways; n=12,551 SNPs) genotypes from
the discovery population VTE cases (objectively-diagnosed; no cancer, catheter or
antiphospholipid antibodies; n=1503) and controls (frequency-matched on case age, gender,
race, MI/stroke status; n= 1459) were merged and imputed to ~2.5 million SNPs (i.e., in
silico genotypes) with MACH using HapMap Phase II (60 CEU).[21] All genetic
coordinates in tables and figures refer to HapMap release 22 build 36. In regions where no
candidate gene genotypes were available, only subjects with GWS data were used for the
imputation.
The primary outcome was VTE status, a binary measure. The covariates were age at
interview or blood sample collection, sex, stroke/MI status and USA state of residence
(Supplementary Table 1). We tested for an association between each SNP and VTE using
unconditional logistic regression, adjusting for age, sex, stroke/MI status and USA state of
residence using PLINK v 1.07.[22] A similar analysis was performed for the replication
study and the covariates were age at interview or blood sample collection, sex and USA
state of residence (Supplementary Table 3). Haplotype analyses were performed on the 25
chromosome 1q.24.2 SNPs most significantly associated with VTE, considering 25- and 10-
SNP-sliding-windows, as implemented in PLINK v 1.07.[22] Novel ABO SNVs identified
by resequencing were tested for an association with VTE using age-, sex-adjusted
unconditional logistic regression and Fisher’s Exact Test. Population attributable risk (PAR)
was estimated for F5 rs6025 (Factor V Leiden), F2 rs1799963 (prothrombin G20210A) and
ABO blood type haplotype, as previously performed.[7]
VTE prevalence was estimated using the resources of the Rochester Epidemiology Project
which has mapped Olmsted County, MN, USA residency for over 500,000 people from
1/1/1966 to 12/31/2010. All Olmsted County residents with objectively-diagnosed, incident
VTE over the 40-year period, 1966-2005, have been followed forward in time until death or
last follow-up. VTE point prevalence was recorded for 1/1/2006 using these data and
adjusted to the USA white population data from the 2000 Census.
Results
Discovery in silico GWAS results
Among the 1503 VTE cases and 1459 controls in the discovery population, the age and sex
distributions were similar between cases and controls; however we found a significant
difference between VTE cases and controls for prior stroke or myocardial infarction (stroke/
MI); and USA state of residence (Supplementary Table 1). From the population
stratification analysis, 98.64% of samples were classified as European and 1.36% as “other”
ancestry (includes individuals of mixed ancestry; Supplementary Figure 1). Since age, sex,
prior stroke or myocardial infarction have been shown or suggested to be risk factors for
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VTE,[1] and due to the significant difference between VTE cases and controls regarding
USA state of residence, we adjusted for these four characteristics in the logistic regression
analyses.
After adjusting for age, sex, stroke/MI and USA state of residence, 39 SNPs exceeded
genome-wide significance (P≤5 × 10-8; Figure 1A and Supplementary Table 2); F2
rs1799963 (prothrombin G20210A) was borderline significant (OR=2.46, P=1.7 × 10-6).
The quantile-quantile plot of the expected vs. observed genome-wide −log(P-values)
(Supplementary Figure 2) shows the impact of chromosome regions 1q24.2 and 9q on VTE
risk. Table 1 shows the association results for significant SNPs not in LD within a gene (F5
rs6025, BLZF1 rs7538157, NME7 rs16861990, SLC19A2 rs2038024, and ABO rs2519093,
rs8176719 [ABO blood type non-O] and rs495828).
Replication and combined results findings
In the separate replication population consisting of 1407 VTE cases and 1418 controls, no
significant difference was found between age, sex, and USA state of residence
(Supplementary Table 3). Because BLZF1 rs7538157 was in high LD with F5, SLC19A2
and ATP1B1, the BLZF1 SNP (rs7538157) was replaced by ATP1B1 rs12061601 (Figure
1B). After adjusting for age, sex and USA state of residence, F5 rs6025 (P=1.4 × 10-12),
NME7 rs16861990 (P=4.9 × 10-9), and ABO rs2519093 (P=1.2 × 10-17), rs495828 (P=2.4 ×
10-17) and rs8176719 (P=5.7 × 10-16), were significantly associated with VTE, while
ATP1B1 rs12061601 (P=0.02), F2 rs1799963 (P=0.03) and SLC19A2 rs2038024 (P=0.09)
were marginally associated (Table 2a). All replicated SNP ORs were in the same direction
and of similar magnitude as that of the discovery population.
These SNPs cluster in two genomic regions located on chromosome 1q24.2 (Figure 1B) and
on chromosome 9q (Figure 1C). Chromosome 1q24.2 and 9q LD patterns observed in
controls are shown in Supplementary Figures 3 and 4, and the ORs and respective 95%
confidence intervals for an association of SNPs in these two genomics regions with VTE are
depicted in Supplementary Figures 5 and 6. Since ATP1B1, NME7, BLZF1 and SLC19A2
are in close proximity to F5, we repeated the association analysis including the F5 rs6025 T
(minor) allele (Factor V Leiden) as a covariate and found that only the ABO SNPs remained
significantly associated with VTE at the genome-wide level. Similarly, in the replication
study only the ABO SNPs and SLC19A2 rs2038024 remained significantly associated with
VTE after adjusting for F5 rs6025 T. Although SLC19A2 rs2038024 was marginally
associated with VTE, the OR was in the opposite direction from that of the discovery
population, suggesting a spurious association (Table 2b).
Receiver Operator Characteristic areas under the curve (AUC), calculated individually and
jointly using all significant SNPs, were not different for covariates (age, sex, stroke/MI and
USA state of residence) plus F5 rs6025 T (AUC=0.653) compared to covariates plus F5
rs6025 T, ATP1B1 rs12061601, NME7 rs16861990 and SLC19A2 rs2038024
(AUC=0.653), while addition of ABO SNPs did increase the AUC (AUC=0.675; Figure 2).
Haplotype analysis results
Haplotype analysis of the 25 chromosome 1q.24.2 SNPs (including ATP1B1, NME7,
BLZF1, C1orf114, SLC19A2, F5 and SELP; Figure 1B and Supplementary Table 4) most
significantly associated with VTE showed that only the two haplotypes containing F5
rs6025 T were significantly associated with VTE (Table 3). Together, these data suggest that
this chromosome 1q24.2 region is inherited as a haplotype block of ~0.52mb. Among all F5
rs6025 T carriers (N=369; 280 cases and 89 controls; 186 males and 183 females), 235
(63.7%; 177 cases and 58 controls) carriers inherited at least one of these two 1q24.2
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haplotypes. The haplotype containing the F5 rs6025 T and the SELP rs3917862 G (minor)
alleles slightly increased the association of the haplotype with VTE (OR=3.59) compared to
the haplotype containing the F5 rs6025 T and the SELP rs3917862 A alleles (OR=3.16,
Table 3). However, a 10-SNP-sliding-window with nine SNPs in F5 (including the F5
rs6025 T allele) and one SNP in SELP (SNP rs3917862 G [minor] allele) considerably
increased the association of this haplotype with VTE (OR=4.55, P=2.07 × 10-13) compared
to the association for the haplotype containing the F5 rs6025 T and SELP rs3917862 A
alleles (OR=3.09, P=1.83 × 10-11; Supplementary Table 5).
Resequencing results
To further evaluate ABO sequence variation for an association with VTE, we performed
ABO resequencing, including 10 Kb of the flanking regions, using Illumina HiSeq 2000.
Excluding the intronic repeat regions, 98% of the targeted area (Supplementary Figure 7)
was sequenced with > 20X coverage in 96 samples (82 VTE cases and 14 controls). On
average, ~35-40 SNVs and ~5-10 insertion-deletions (INDELs) were detected in each
sample. Fifteen novel SNVs in ABO intron 6 and the ABO 3’ UTR were associated with
VTE (all P<10-04) and belonged to three distinctive LD blocks; none were in LD with ABO
rs8176719 (blood type O allele) or rs2519093 although ABO rs8176746 (blood type A
allele) and rs8176747 (blood type B allele) were in moderate LD (r2=0.56-0.65) with novel
SNPs in block 3 (Figure 3; Supplementary Table 6). Although ABO rs8176746 and
rs8176747 did not reach genome wide significance in the primary analysis, a secondary
analysis (adjusted for age, sex, stroke/MI and USA state of residence) of the derivation
population that considered ABO blood type (either haplotype/genotype or phenotype; VTE
cases, n=1459; controls, n=1422) found strong associations of ABO blood types A
(OR=1.64; 95%CI: 1.41, 1.91; P=7.83 × 10-11) and O (OR=0.52; 95%CI: 0.44, 0.60; P=2.40
× 10-16) with VTE, but no association with blood types B (OR=1.15; 95%CI: 0.91, 1.44;
P=0.25) or AB (OR=1.22; 95%CI: 0.87, 1.70; P=0.25; Supplementary Table 7). Finally, a
significant, protective, frame-shifting single base (G) deletion of one of three guanines at
ABO chr9:135120878-80 was found within exon 7. This deletion likely corresponds to ABO
rs8176750 (ABO blood-type A2).
The individual, joint and group population attributable risk (PAR) were calculated for the
risk genotypes for Factor V Leiden (F5 rs6025), prothrombin G20210A (F2 rs1799963), and
ABO blood type haplotype or genotype (Supplementary Table 8). The highest PAR value
was from the ABO blood type non-O, followed by ABO blood type A, Factor V Leiden, and
prothrombin G20210A. The PAR values were very similar between the joint and group
estimation methods, with highest joint or group PAR (PAR=0.47) for ABO blood type non-
O, F5 rs6025 and F2 rs1799963).
Discussion
Our most notable finding was the strong association of VTE with three novel and distinctive
ABO LD blocks that were independent of ABO type O blood type. ABO encodes for
glycosyltransferases responsible for post translational glycosylation of procoagulant FVIII
and von Willebrand Factor (VWF).[23] ABO O blood group phenotype and genotype (i.e.,
ABO rs8176719) is associated with a decreased risk for VTE,[7, 8, 24] presumably due to
decreased plasma levels of FVIII and VWF.[25, 26] ABO-mediated glycosylation protects
VWF from proteolysis by ADAMTS13[27] such that individuals with type O blood group
(homozygous exon 6 ABO rs8176719 deletion) and hypoglycosylated VWF have ~25%
lower plasma FVIII and VWF levels.[24, 28]
We previously identified an independent association of an ABO intron 1 SNP (rs2519093)
with VTE (OR=1.68, P=8.08×10-16).[7] This intronic region does not affect RNA splicing or
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harbor any suppressor RNA elements, nor is it close to any other ABO variants with known
function, including variants in ABO exons 6 and 7 that have been variably associated with
VTE risk.[29-33] Of the 15 novel ABO SNVs found on resequencing, none were in LD with
this ABO intron 1 SNP (Figure 3; Supplementary Table 6). Consequently, the findings of
this study expand on our previous observation and suggest that this ABO intron 1 region
along with an LD block in ABO intron 6 and two LD blocks in the ABO 3’ UTR play
important roles in ABO expression and associated VTE risk.
In a secondary analysis, the ABO blood type A haplotype was strongly associated with VTE
(Supplementary Table 7) as previously described.[31-34] In the limited and select sample
(n=96) of our discovery population who underwent ABO resequencing, the ABO A allele
was in moderate LD (r2=0.56-0.65) with SNVs in ABO LD block 3 (Figure 3) which
potentially could account for the association of these novel block 3 SNVs with VTE. The
association of VTE with novel SNVs in ABO LD block 2 was independent of blood type A
(rs8176747) and O (rs8176719) alleles, and ABO rs2519093 (Figure 3). ABO LD block 2
may be important for gene regulation due to a potential open chromatin region as reflected
by enrichment for multiple epi-genetic markers in the region,(ENCODE: http://
www.genome.gov/10005107) a transcription factor binding site (ChIP-seq, ENCODE:
http://www.genome.gov/10005107), and evolutionary conservation (UCSC phatCons[35]
and phylo[36] algorithms; Figure 4). In addition, strong evidence from dbEST supports the
middle LD block as also lying within a novel transcript, probably an extension of the 3’ of
ABO (dbEST: http://www.ncbi.nlm.nih.gov/dbEST/; Figure 4). ABO SNV_135116452 was
not part of any ABO LD block but it was in high LD with SNVs from LD block 3, and in
moderate (r2=0.54) LD with the ABO blood type A allele (rs8176747; Figure 3). Thus, the
association of SNV_135116452 with VTE may also be due to blood type A. Lastly, the
SNVs in ABO LD block 1 are in low LD with all the other SNVs and SNPs (Figure 3). The
associations of SNVs in LD block 1 with VTE are independent of blood type A
(r2~0.27-0.44) and O (r2~0-0.02) alleles, and ABO rs2519093 (r2~0-0.04; Figure 3).
Our ABO resequencing data also support the previously reported association of VTE with
ABO blood type A2 (ABO rs8176750).[8, 31] Although we did not directly genotype ABO
rs8176750 in either our CG or GWAS studies, one directly-genotyped ABO SNP
(rs8176704) in strong LD with rs8176750 (r2≥0.8) was associated with a significantly
reduced risk of VTE (OR=0.78; 95%CI: 0.63, 0.97, P=0.02) that was of similar magnitude
to that reported for ABO blood type A2.[8, 31] The ABO rs8176750 deletion results in a
frame-shift that abrogates the wild-type stop codon within exon 7 and likely leads to an
elongated transcript (Figure 4) and an absent or dysfunctional protein similar to blood type
O.
Our second notable finding was the discovery that Factor V Leiden is inherited as a
haplotype block that spans seven genes on chromosome 1q24.2, including ATP1B1, NME7,
BLZF1, C1orf114, SLC19A2, F5 and SELP. F5 encodes for plasma procoagulant Factor(F)
V; FV accelerates activation of prothrombin to thrombin by catalyzing assembly of the
prothrombinase complex. FV inactivation is key for down-regulating procoagulant activity.
Activated Protein C (APC), a serine protease, inactivates FV via cleavage at arginine[R]306,
R506 and R679; initial APC cleavage at R506 is required for rapid FV inactivation by APC
cleavage at R306 and R679.[37] F5 rs6025 encodes for substitution of glutamine for R506.
[38, 39] Factor V Leiden carriers have normal FV procoagulant activity but impaired FV
down-regulation due to “resistance” to cleavage/inactivation by APC.[40, 41] Factor V
Leiden is a founder mutation occurring about 30,000 years ago,[42] and is associated with
~3.5-fold increased risk for VTE (lifetime VTE penetrance ~5%).[7, 38, 43]
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Our third finding was that the tag SNP SELP rs3917862 compounds the risk of VTE among
Factor V Leiden carriers. SELP encodes for P-Selectin, a membrane glycoprotein with pro-
inflammatory activity that mediates the interaction between activated platelets, leukocytes,
immune cells and endothelial cells.[44, 45] Cell-surface P-selectin expression and soluble P-
selectin concentration are partly controlled by SELP genetic variation.[46, 47] Increased
soluble P-selectin plasma levels are associated with incident and recurrent VTE.[48, 49] We
previously showed that SELP rs3917862 was associated with a 1.6-fold increased risk of
VTE at a false discovery rate q = 0.006.[7] SELP is located immediately upstream from F5
(Figure 1B), and associations between SELP haplotypes and VTE have been attributed to
high LD with F5 rs6025 T.[50] In our previous report, while SELP rs3917862 was not in
high LD with F5 rs6025 T (r2=0.12, D’=0.37), the association of rs3917862 with VTE was
no longer significant (P=0.3) after controlling for F5 rs6025 T.[7] Our new analyses indicate
that the haplotype containing the F5 rs6025 T and the SELP rs3917862 G (minor) alleles
increases the association of the haplotype with VTE (OR=3.59) compared to the haplotype
containing the F5 rs6025 T and the SELP rs3917862 A alleles (OR=3.16, Table 3).
Furthermore, the association of the haplotype with VTE increases when considering
different numbers of SNPs in the sliding window approach (OR=4.55 for 10-SNP-sliding-
window with nine SNPs in F5 and one in SELP; Supplementary Table 5). Based on these
statistical analyses, we conclude that the SELP rs3917862 T allele compounds the risk of
VTE associated with F5 rs6025 T.
Although we found associations of VTE with ATP1B1, NME7, BLZF1, and SLC19A2,
these associations disappeared in both the discovery and replication populations after
controlling for F5 rs6025 T (Factor V Leiden). ATP1B1 encodes for a Na+/K+ ATPase
important in endothelial cell and platelet function, NME7 encodes for a nucleoside-
diphosphate kinase important in erythropoiesis and CD4 T-cell activation, BLZF1 (JEM-1)
encodes for basic leucine zipper nuclear factor 1 which is important for the response of acute
promyelocytic leukemia to retinoic acid, and SLC19A2 encodes for a thiamine transporter
protein (THTR-1) implicated in thiamine-responsive megaloblastic anemia. While the
products of these genes are potentially biologically plausible in the causal pathway to VTE,
none have been previously associated with VTE. Moreover, ROC curve analyses showed
that SNPs within these four genes added no additional information over that provided by
patient characteristics and F5 rs6025 T alone. Thus, we believe it is unlikely that these genes
are VTE disease-susceptibility genes.
Our sample size provided 80% power to detect odds ratios of 2.0 and 1.51 for minor allele
frequencies (MAF)=0.05 and 0.5, respectively (α=5 × 10-8) based on a 1% prevalence of
VTE among USA whites for the year 2000.[51] While single studies or individual-level data
meta-analyses with a larger sample size and/or more dense genome-wide scan genotype data
may identify additional SNPs that associate with VTE, we believe that aside from F5
rs6025, ABO rs8176719 and rs2519093, and F2 rs1799963, additional common (i.e.,
MAF>0.05) and high VTE-risk (i.e., OR>2.0) SNPs among persons of non-Hispanic
European ancestry are unlikely.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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A. Manhattan plot of –log10(P-values) from the case-control association analysis on the
merged/imputed VTE data assuming an additive genetic model. The horizontal line at 1.99 ×
10-08 represents the Bonferroni correction. Figure 1B. Location and linkage disequilibrium
for SNPs on chromosome 1q24.2 surrounding F5. The black diamond corresponds to F5
6025 (Factor V Leiden) the most significant SNP. Figure 1C. Location and linkage
disequilibrium for SNPs on chromosome 9q surrounding ABO. The black diamond
corresponds to the most significant SNP, rs495828. For Figures 1B and 1C, the linkage
disequilibrium measure, r2, between the most significant SNP and any other SNP in the
region is symbol coded; the square, star, triangle, circle, and cross symbols correspond to r2
> 0.95, > 0.8 and ≤ 0.95, > 0.5 and ≤ 0.8, > 0.2 and ≤ 0.5, and ≤ 0.2, respectively.
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Receiver Operator Characteristic (ROC) Curve Analyses of Chromosome 1q24.2 and ABO
SNPs
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Linkage disequilibrium (LD) between novel ABO SNVs identified by resequencing, and
ABO rs8176474 (blood type A allele), rs8176746 (blood type B allele), rs8176719 (blood
type O allele) and rs2519093 (ABO intron 1), among 82 VTE cases and 14 controls selected
based on ABO rs8176719 and rs2519093 genotype (see Methods). The numbers inside each
square and the square shading indicate the degree of LD between SNPs and/or SNVs (i.e.,
black squares with no number indicate complete LD [r2=1.0]; intensity of the gray shading
indicates intermediate values between complete LD [r2=1.0] and no LD [r2=0.0], and white
squares with 0 number indicate no LD).
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Potential functional roles of ABO SNVs identified on resequencing, by LD block or
deletion.
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